REDHILL BIOPHARMA LTD-SP ADR (RDHL)
US7574683014 - ADR
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the...
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has...
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates...
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program...
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation...
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical...
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for...
RedHill Biopharma Announces First Half 2024 Business Highlights
A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik...
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of...
Talicia® Launched in the United Arab Emirates
RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat...
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034[1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors...
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to...
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
One of today's biggest market movers in the biotech space is RedHill Biuopharma, with RDHL stock up more than 75% on big news.
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary endpoint of clinical remission...
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a...
RedHill Biopharma Terminates License Agreement for Aemcolo®
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision...
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer...
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035...
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded...
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia...
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by...
RedHill Biopharma files to sell 10.6M ADS for holders (NASDAQ:RDHL)
Read about RedHill Biopharma's filing of a prospectus for the resale of 10.6M ADSs, representing 400 shares each, by selling stockholders.
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...
RedHill Biopharma Announces $8 Million Registered Direct Offering
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
RedHill gains on patent grant for Talicia for H. pylori treatment (NASDAQ:RDHL)
RedHill Biopharma's new patent for Talicia, a method for eradicating H.
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
USPTO issues new patent covering Talicia[1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI)[2], supporting Talicia protection...